Matched stent cover

Information

  • Patent Grant
  • 12357446
  • Patent Number
    12,357,446
  • Date Filed
    Tuesday, October 9, 2018
    7 years ago
  • Date Issued
    Tuesday, July 15, 2025
    3 months ago
Abstract
Various aspects of the present disclosure are directed toward implantable medical devices that include a frame and a tubular member attached to the frame. The tubular member includes one or more fibrils or a strength in alignment with one or more struts of the frame.
Description
BACKGROUND

Medical stents are generally known. Stents, in combination with coverings, also can be used for the endovascular repair of aneurysms, an abnormal widening or ballooning of a portion of a body lumen which can be related to weakness in the wall of the body lumen. Various stent designs are known in the art. Stents typically are tubular, and are expandable or self-expand from a relatively small diameter to a larger diameter.


Braided stents are popular for bare metal constructs. Covering a braided stent has challenges in that the covering will wrinkle, stretch, or tear if it does not move in tandem with the wires.


SUMMARY

According to one example, (“Example 1”), an implantable medical device includes a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame; and a tubular member attached to the frame and including fibrils extending along the plurality of struts and configured to maintain alignment with the plurality of struts.


According to another example, (“Example 2”) further to Example 1, the fibrils of the tubular member are axially aligned with the plurality of struts.


According to another example, (“Example 3”) further to Examples 1 or 2, the fibrils extend in parallel with the plurality of struts.


According to another example, (“Example 4”) further to Examples 1-3, the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.


According to another example, (“Example 5”) further to Example 4, the geometry of the plurality of struts changes in response to at least one of a length change of the frame and a circumferential change of the frame, and the fibrils are configured to orient with the plurality of struts in a direction extending toward the proximal end of the frame and a direction extending toward the distal end of the frame.


According to another example, (“Example 6”) further to Examples 1-5, the plurality of struts include a first set of struts that extend at a first pitch toward the proximal end and a second set of struts that extend at a second pitch toward the distal end, and the fibrils include a first set of fibrils that extend at approximately the first pitch toward the proximal end and a second set of fibrils that extend at approximately the second pitch toward the distal end.


According to another example, (“Example 7”) further to Example 6, the first set of fibrils overlap with the second set of fibrils throughout the tubular member.


According to another example, (“Example 8”) further to Example 7, the fibrils are configured to shear relative to one another to maintain alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame.


According to another example, (“Example 9”) further to Examples 1-8, the tubular membrane is configured to allow expansion and contraction of the frame in response to at least one of a length change of the frame, a circumferential change of the frame, and angular displacement of the frame.


According to another example, (“Example 10”) further to Example 9, the tubular member is configured to resist residual elastic strain acting against frame deformation in response to at least one of the length change of the frame, the circumferential change of the frame, and the angular displacement of the frame.


According to another example, (“Example 11”), an implantable medical device includes a frame having a plurality of struts overlapping and helically extending between a proximal end and a distal end of the frame; and a tubular member attached to the frame and including a primary strength oriented with the plurality of struts, the tubular member configured to maintain orientation of the primary strength with the plurality of struts in response to a force applied to the frame.


According to another example, (“Example 12”) further to Example 11, the tubular member includes a first set of fibrils aligned with the plurality of struts to form the primary strength of the tubular member and a second set of fibrils unaligned with the plurality of struts.


According to another example, (“Example 13”) further to Example 12, the tubular member includes a greater number of the first set of fibrils than a number of the second set of fibrils.


According to another example, (“Example 14”) further to Examples 12-13, lengths of the first set of fibrils are greater than lengths of the second set of fibrils.


According to another example, (“Example 15”) further to Examples 12-14, the first set of fibrils of the tubular member are axially aligned with the plurality of struts.


According to another example, (“Example 16”) further to Examples 11-14, the tubular member forms a continuous flow lumen.


According to another example, (“Example 17”), a method includes deploying an implantable medical device into a body, the implantable medical device including a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame and a tubular member attached to the frame having fibrils extending along the plurality of struts in alignment with the plurality of struts; and maintaining alignment of the fibrils with the plurality of struts in response to altering a geometry of the stent.


According to another example, (“Example 18”) further to Example 17, maintaining alignment of the fibrils includes the fibrils shearing relative to one another to maintain alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame.


According to another example, (“Example 19”) further to Examples 17 or 18, the fibrils of the tubular member are axially aligned with the plurality of struts.


According to another example, (“Example 20”) further to Examples 17-19, the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.


According to another example, (“Example 21”), an implantable medical device includes a frame having at least one strut arranged in a first direction; and a tubular member attached to the frame and including a strength element oriented with the at least one strut in the first direction and the strength element is configured to bias the at least one strut in the first direction.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows an example stent, consistent with various aspects of the present disclosure.



FIG. 2 shows an example stent and tubular member in a non-deformed configuration, consistent with various aspects of the present disclosure.



FIG. 3 shows another example stent and tubular member in a deformed configuration, consistent with various aspects of the present disclosure.



FIG. 4A shows another example tubular member in an undeformed state, consistent with various aspects of the present disclosure.



FIG. 4B shows another example tubular member in a deformed state, consistent with various aspects of the present disclosure.



FIG. 5 shows another example stent and tubular member, consistent with various aspects of the present disclosure.



FIG. 6 shows an example laser-cut stent, consistent with various aspects of the present disclosure.



FIG. 7A shows an image of an example tubular member having a strength aligned in a first direction, consistent with various aspects of the present disclosure.



FIG. 7B shows a close-up view of the image of an example tubular member, in FIG. 7B, consistent with various aspects of the present disclosure.





DETAILED DESCRIPTION

Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatuses configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.


A medical device, consistent with various aspects of the present disclosure, is a device adapted to be inserted into a body and then deployed within the body. Such medical devices may be deployed within an artery or other vessel. Most generally, medical devices according to various examples assist in structurally supporting the host vessel lumen, maintaining patency through the vessel, passageway or opening, repairing vessels having an intimal flap or dissection, or isolating sections of a host vessel lumen, such as aneurysms. The medical devices may be shaped and sized and otherwise customized to fit a particular anatomy, including adjusting its length and inside diameters. The medical devices may include a stent with a framework of struts (or relatively rigid sections) and also may include a graft coupled or attached to the framework of struts.


Grafts or coverings in combination with the stent may help minimize or at least reduce the risk of introduction of emboli into a bloodstream, resist tissue encroachment into the lumen defined by the stent, reduce pressure on a weakened part of a blood vessel to reduce the risk of vessel rupture, and/or to create a conduit for attaching at least two vessels. The grafts or coverings may be made from continuous materials with no holes visible without magnification. Various grafts or coverings may be attached to the luminal (interior) or exterior surface of the stent.


In addition, the medical devices discussed herein may include braided or helical frames. The braided or helical frames may include a plurality of struts that overlap as the plurality of struts extends between ends of the medical devices. During deployment, geometry change, or other shape change of the braided frames, helical frames, or other frames, a graft or covering attached to the stent may encumber the stent's ability to expand. As discussed in further detail below, the medical devices discussed herein include tubular members (e.g., grafts or coverings) that interact and cooperate with the framework (to which the tubular members are attached) to ensure accurate deployment and functioning of the medical devices, for example with an inelastic or substantially inelastic covering or tube.



FIG. 1 shows an example stent 100, consistent with various aspects of the present disclosure. The stent 100 (or frame) includes a plurality of struts 102 that extend between a proximal end 104 and a distal end 106 of the stent 100. The stent 100 may be a support structure for an implantable medical device (e.g., an occluder, filter, or other similar device) formed by the plurality of struts 102. As shown in FIG. 1, the struts 102 form a tubular structure and it is understood that the struts 102 may form a non-cylindrical structure in certain instances. The plurality of struts 102 may overlap between the proximal end 104 and the distal end 106 of the stent 100. The plurality of struts 102 may be considered a braided stent. In addition, the plurality of struts 102 traverse a circumference of the stent 100 in lengthwise but angularly intersecting directions. The two directional sets of struts are interlaced or interwoven to form a tubular, supportive structure. In certain instances, the stent 100 may be a helical construct



FIG. 2 shows an example stent 100 and tubular member 208 in a non-deformed configuration, consistent with various aspects of the present disclosure. The stent 100 and tubular member 208 form an implantable medical device. The tubular member 208 may be formed of an oriented polymer with a low shear strength direction (e.g., expanded PTFE (ePTFE)). The tubular member 208 may have a strength in one direction that is higher than a strength in another direction such that when a shear force is induced on or to the tubular member 208 (e.g., by way of stent 100 altering shape), the tubular member 208 is configured to reorient with the shear force. The tubular member 208 may stretch without wrinkling or tearing. The tubular member 208 is configured to move in tandem with the stent 100. In this regard, the tubular member 208 may include fibrils 210, 212, which are labeled and are represented generally in FIG. 2. It should be understood that, according to various embodiments, the fibrils 210, 212 are not readily seen by the naked eye (e.g., as shown in FIG. 5). As shown, the tubular member 208 may include fibrils 210, 212 that are aligned with the plurality of struts 102. The fibrils 210, 212 optionally extend along the plurality of struts 102 and are aligned with the plurality of struts 102, according to various embodiments.


As shown in FIG. 2, the plurality of struts 102 form a frame by overlapping and helically extending between the proximal end 104 and the distal end 106 of the medical device. The plurality of struts 102 are wound such that adjacent ones of the plurality of struts 102 extend in opposite directions (e.g., left handed and right handed helices). For example, a first strut 214 of the plurality of struts 102 may extend upward and toward the proximal end 104 at a location on the stent 100, whereas the second strut 216 (adjacent to the first strut 214) of the plurality of struts 102 extends upward and toward the distal end 106 of the stent 100 at that particular location. The first strut 214 represents a left handed helix, and the second strut 216 represents a right handed helix. Although the stent 100 includes a plurality of struts 102, single ones of the first strut 214 and the second strut 216 are highlighted for ease of understanding. Various other struts are shown in FIG. 2 and are arranged and extend similarly to the designated first strut 214 and designated second strut 216, and as such are similarly considered to be a first strut 214 and second strut 216.


In certain instances, the fibrils 210, 212 of the tubular member 208 are axially aligned with the plurality of struts 102. For example, tubular member may include a first set of fibrils 210 and a second set of fibrils 212 as shown in FIG. 2. The first set of fibrils 210 may be aligned with the helices of the first direction (e.g., the second strut 216 of the plurality of struts 102) and the second set of fibrils 212 may be aligned with the helices of the second direction (e.g., the first strut 214 of the plurality of struts 102). In certain instances, the fibrils 210, 212 extend in parallel with the plurality of struts 102. For example, the first set of fibrils 210 extend parallel to the first struts 214 and other similarly extending struts of the plurality of struts 102 shown in FIG. 2 and the second set of fibrils 212 and other similarly extending struts of the plurality of struts 102 shown in FIG. 2. Although the tubular member 208 includes multitude of fibrils 210, 212, single ones of the first set of fibrils 210 and the second set of fibrils 212 are highlighted for ease of understanding. The other fibrils shown in FIG. 2 that are arranged and extend similarly to the designated one of the first set of fibrils 210 and designated one of the second set of fibrils 212 are also considered to be, respectively, part of the first set of fibrils 210 and the second set of fibrils 212.


In certain instances, the plurality of struts 102 are braided and extend helically between the proximal end 104 and the distal end 106. The fibrils 210, 212 are configured to align with a geometry of the plurality of struts 102. For example, the fibrils 210, 212 extend at the same pitch angle at which the plurality of struts 102 extend. In addition and as noted above, the plurality of struts 102 are angled such that adjacent ones of the plurality of struts 102 extend in intersecting directions to form the braided stent 100. The first strut 214 and the first set of fibrils 212 may extend upward and toward the proximal end 104 at a location on the stent 100, whereas the second strut 216 (adjacent to the first strut 214) and the second set of fibrils 212 extends upward and toward the distal end 106 of the stent 100 at that particular location.


In addition to being aligned with the plurality of struts 102, the fibrils 210, 212 are configured to maintain alignment with the plurality of struts 102. The fibrils, for example, maintain alignment with the plurality of struts 102 when the stent 100 changes configuration, geometry, or shape as is described in further detail with reference to FIG. 3.



FIG. 3 shows another example stent 100 and tubular member 208 in a deformed configuration, consistent with various aspects of the present disclosure. As compared to the stent 100 and tubular member 208 shown in FIG. 2, the stent 100 and tubular member 208 have been reduced in circumference (e.g., compressed) and elongated. The deformed configuration shown in FIG. 3, may be a delivery configuration for the stent 100 and tubular member 208, or a configuration of the stent 100 and tubular member 208 as the result of forces acting on the stent 100 and/or the tubular member 208 (e.g., after implantation in a patient).


As noted above with reference to FIG. 2, for example, fibrils 210, 212 are configured to maintain alignment with the plurality of struts 102 in addition to being aligned with the plurality of struts 102. The fibrils, for example, maintain alignment with the plurality of struts 102 when the stent 100 changes configuration, geometry, or shape. As shown in FIG. 3, the plurality of struts 102 have reoriented as a result of being reduced in diameter. Due to the helical/braided configuration of the plurality of struts 102, the stent 100 has also elongated in comparison to the non-deformed or non-altered stent 100 shown in FIG. 2. The angle at which the plurality of struts 102 extend helically has also decreased relative to the non-deformed or non-altered stent 100 shown in FIG. 2. For example, in some examples the angle by which the plurality of struts 102 extend helically changes by greater than zero and less than 90 degrees according to various examples when the stent is transitioned from the first to the deformed state. The fibrils 210, 212 also change pitch angle in the same manner in which the plurality of struts 102 change pitch angle as shown in FIG. 2. The stent 100 and the tubular member 208 deform in conjunction with one another by way of the plurality of struts 102 and the fibrils 210, 212 re-orienting in tandem.


In certain instances, a geometry of the plurality of struts 102 changes in response to at least one of a length change of the stent 100 (e.g., the frame), a circumferential change of the stent 100, or angular displacement of the struts of the stent 100. Similarly, the fibrils 210, 212 are configured to orient with the plurality of struts 102. The fibrils 210, 212 and the plurality of struts 102 orient in a direction extending toward the proximal end 104 of the stent 100 and a direction extending toward the distal end 106 of the stent 100. In certain instances, the plurality of struts 102 include a first set of struts, represented by the first strut 214, that extend at a first pitch toward the proximal end 104 and a second set of struts, represented by the second strut 216, that extend at a second pitch toward the distal end 106. Similarly, the first set of fibrils 210 extend at approximately the first pitch toward the proximal end 104 and the second set of fibrils 212 extend at approximately the second pitch toward the distal end 106. As shown in comparing FIG. 2 and FIG. 3, the first set of fibrils 210 and the first set of struts, represented by the first strut 214, alter pitch angles in coordination with one another, and the second set of fibrils 212 and the second set of struts, represented by the second strut 216, alter pitch angles in coordination with one another.


In certain instances, the first set of fibrils 210 overlap with the second set of fibrils 212 throughout the tubular member 208. In response to at least one of a length change of the stent 100, a circumferential change of the stent 100 (e.g., as shown comparing FIG. 2 and FIG. 3) or angular displacement of the struts of stent 100, the fibrils 210, 212 are configured to shear (or slip) relative to one another to maintain alignment of the fibrils 210, 212 with the plurality of struts 102. The fibrils 210, 212, for example, shear within the tubular member 208 to maintain alignment with the plurality of struts 102. The tubular member 208 forms a continuous flow lumen by way of the fibrils 210, 212. The tubular member 208 may be an impermeable membrane or film.


In certain instances, the fibrils 210, 212 being configured to maintain orientation with the plurality of struts 102 allows the stent 100 to expand and contract in response to at least one of a length change of the frame, a circumferential change of the stent 100, or angular displacement of the struts of the stent 100. The fibrils 210, 212 do not otherwise encumber or restrict the ability of the stent 100 to change geometry or expand and contract. More specifically and in certain instances, the tubular member 208, by way of the fibrils 210, 212, is configured to resist residual elastic strain acting against stent 100 deformation in response to at least one of the length change of the frame, the circumferential change of the stent 100, or angular displacement of the struts of the stent. The tubular member 208 does not include residual elastic strain that acts against the stent 100 changing geometry under deformation of the stent 100.


The tubular member 208 may include non-oriented fibrils 318 in addition to the fibrils 210, 212 that are not oriented with the plurality of struts 102. The non-oriented fibrils 318 (represented by the open space between the fibrils 210, 212) may fill connect and fill space between the fibrils 210, 212. The non-oriented fibrils 318 are those fibrils of the tubular member 208 that are not oriented or aligned with primary strength of the tubular member 208.


The fibrils 210, 212 that are aligned with struts 102 of the stent 100 may have a greater strength than fibrils or nodes that connect the strength fibrils together For example, the tubular member can be made from a film that has a force to break strength direction of 1.06 kgf/cm and a force to break transverse direction strength of 0.024 kgf/cm as measured by a tensile testing machine. Other ratios of strength to transverse direction may be used dependent on application. For example a ratio of strength direction to transverse direction may be 30, 35, 40, 45, 50, 55, 60 or more. In addition, the fibrils 210, 212 that are aligned with struts 102 of the stent 100 also have a greater length greater than lengths of the fibrils that are unaligned with the struts 102 of the stent 100 and also maintain alignment with the struts 102 of the stent 100.


In certain instances, the tubular member 208 may include a single set of fibrils 210 that are aligned with struts 102 of the stent 100. The tubular member 208 may have a single strength direction oriented with the stent 100.



FIG. 4A shows another example tubular member 408 in an undeformed state, consistent with various aspects of the present disclosure. The tubular member 408 is a weave or knit material. The tubular member 408 may have a strength element that is aligned with one or more struts of a stent (e.g., as shown in FIG. 1 or FIG. 6). The tubular member 408 may be attached to a stent that is a continuous frame, as depicted in FIG. 1 or FIG. 6 or a plurality of discrete rings to form a stent frame. In addition, the tubular member r408 may be configured to maintain orientation of the strength element with the strut on response to a force applied to the stent. The strength element of the tubular member 408 is configured to maintain orientation in response to a force acting on the tubular member 408.


As shown in FIG. 4A, the tubular member 408 member includes a series or woven or knit filaments, threads, or fibers 410, 412. The filaments, threads, or fibers 410, 412 may form the strength element. In addition, the tubular member 408 may have a strength in one direction that is higher than a strength in another direction such that when a shear force is induced on or to the tubular member 408 (e.g., by way of stent 100, to which the tubular member 408 is attached, altering shape), the tubular member 408 is configured to reorient with the shear force as shown in FIG. 4B.


As shown in FIG. 4B, the tubular member 408 may stretch without wrinkling or tearing. The tubular member 408 is configured to move in tandem with the stent 100. The tubular member 408 is oriented along with a stent 100, to which the tubular member 408 is coupled to or attached to, maintain orientation of the strength element with the at least one strut in response to a force applied to the frame.



FIG. 5 shows another example stent 100 and tubular member 208, consistent with various aspects of the present disclosure. In certain instances, the tubular member 208 is coupled to the stent 100, having a plurality of struts 102, to form a medical device 500. In certain instances, the tubular member 208 may be formed of expanded PTFE (ePTFE) and attached to the stent 100 using fluorinated ethylene propylene (FEP). The tubular member 208 may be arranged on one side or both sides of the stent 100. The tubular member 208 is attached to the stent 100, in certain instances, such that fibrils contained in the tubular member 208 are aligned with struts that form the stent 100.


The illustrative medical device shown in FIG. 5 is not intended to suggest any limitation as to the scope of use or functionality of embodiments as discussed throughout this disclosure. Neither should the illustrative system be interpreted as having any dependency or requirement related to any single component or combination of components illustrated therein. For example, in various embodiments, the illustrative medical device 500 may have fibrils that are continued to maintain orientation with a plurality of struts of the stent 100 as described with reference to FIG. 1-3. In addition, the tubular member 208 may include a primary strength oriented with the plurality of struts as discussed with reference to FIG. 4.



FIG. 6 shows an example laser-cut stent 600, consistent with various aspects of the present disclosure. The stent 600 may include a plurality of diamond shaped cells 620 (one of which is highlighted in FIG. 6), although the cells 620 may have different shapes such as chevron or rectangle. The laser-cut stent could be a continuous frame as depicted or a plurality of discrete rings to form a stent frame. In addition, the laser-cut stent 600 may include a tubular member 208 attached thereto. As discussed in further detail above, the tubular member 208 may be formed of a polymer with a low shear strength direction (e.g., expanded PTFE (ePTFE)). The tubular member 208 may have a strength in one direction that is higher than a strength in another direction such that when a shear force is induced on or to the tubular member 208 (e.g., by way of stent 600 altering shape), the tubular member 208 is configured to reorient with the shear force. The tubular member 208 may stretch without wrinkling or tearing. The tubular member 208 is configured to move in tandem with the stent 600. In this regard, the tubular member 208 may include fibrils 210, 212, which are labeled and are represented generally in FIG. 6.


As shown in FIG. 6, the stent 600 includes overlapping or crossing struts 102. Although the stent 600 includes a plurality of struts 102, single ones of a first strut 214 and a second strut 216 are highlighted for ease of understanding. Various other struts are shown in FIG. 2 and are arranged and extend similarly to the designated first strut 214 and designated second strut 216, and as such are similarly considered to be a first strut 214 and second strut 216. The fibrils 210, 212 of the tubular member 208 are axially aligned with the plurality of struts 102. For example, tubular member may include a first set of fibrils 210 and a second set of fibrils 212 as shown in FIG. 2. The first set of fibrils 210 may be aligned with the first strut 214 of the plurality of struts 102, and the second set of fibrils 212 may be aligned with the second strut 216 of the plurality of struts 102. In certain instances, the fibrils 210, 212 extend in parallel with the plurality of struts 102. Although the tubular member 208 includes multitude of fibrils 210, 212, single ones of the first set of fibrils 210 and the second set of fibrils 212 are highlighted for ease of understanding. The other fibrils of the tubular member 208 that are arranged and extend similarly to the designated one of the first set of fibrils 210 and designated one of the second set of fibrils 212 are also considered to be, respectively, part of the first set of fibrils 210 and the second set of fibrils 212.


In addition to being aligned with the plurality of struts 102, the fibrils 210, 212 are configured to maintain alignment with the plurality of struts 102. The fibrils, for example, maintain alignment with the plurality of struts 102 when the stent 100 changes configuration, geometry, or shape.



FIG. 7A shows an image of an example tubular member 208 having a strength aligned in a first direction 722, consistent with various aspects of the present disclosure. The strength may be associated with fibrils 212 within the tubular member 208. In addition, the strength of the tubular member 208 may be aligned with a strut of a stent to which the tubular member 208 is attached as discussed in detail above. The tubular member 208 being attached to a stent and aligns the strength of the tubular member 208 with a strut in the first direction 722. As a result, the tubular member 208 is configured to bias the strut in the first direction 722.



FIG. 7B shows a close-up view of the image of an example tubular member 208, in FIG. 7B, consistent with various aspects of the present disclosure.


Suitable materials for use in in the tubular member 208 may include, without limitation, fluoropolymers (especially polytetrafluoroethylene (PTFE) and fluorinated ethylene propylene (FEP)), polyethylenes, polyethylene terephthalate (PET), nylon, polyurethane, polypropylene, polyester, polyimide, etc., as well as composite materials combining these and/or other materials to achieve the desired strength and compliance characteristics. Expanded PTFE (ePTFE) is believed to be most preferred for many applications.


Depending on applications, tubular members of the present disclosure may be constructed from a continuous material, such as continuous films, tapes, or sheets of materials. Alternatively, the tubular members may include discontinuous structures, such as sheets or tapes that include holes or slits therein, or even materials formed from weaves, knits, or other open structures.


Consistent with various aspects of the present disclosure, frames discussed herein may be made from a variety of materials. These materials comprise metals, such as nitinol, stainless steel, tantalum, titanium, tungsten, gold, platinum, iridium, rhodium and alloys thereof or pyrolytic carbon. Other materials comprise polymers such as polyurethane, high density polyethylene, polypropylene, and poly(dimethyl siloxane). Further still, the frames may be formed from biocompatible polymers that are bio-resorbable (e.g., bio-erodible or bio-degradable). Bio-resorbable materials are preferably selected from the group consisting of any hydrolytically degradable and/or enzymatically degradable biomaterial. Examples of suitable degradable polymers include, but are not limited to, polyhydroxybutyrate/polyhydroxyvalerate copolymers (PHV/PHB), polyesteramides, polylactic acid, hydroxy acids (i.e. lactide, glycolide, hydroxybutyrate), polyglycolic acid, lactone based polymers, polycaprolactone, poly(propylene fumarate-co-ethylene glycol) copolymer (aka fumarate anhydrides), polyamides, polyanhydride esters, polyanhydrides, polylactic acid/polyglycolic acid with a calcium phosphate glass, polyorthesters, silk-elastin polymers, polyphosphazenes, copolymers of polylactic acid and polyglycolic acid and polycaprolactone, aliphatic polyurethanes, polyhydroxy acids, polyether esters, polyesters, polydepsidpetides, polysaccharides, polyhydroxyalkanoates, and copolymers thereof. Further still, the tubes may be formed of a polycarbonate material, such as, for example, tyrosine-derived polycarbonates, tyrosine-derived polyarylates, iodinated and/or brominated tyrosine-derived polycarbonates, iodinated brominated tyrosine-derived polyarylates polyhydroxy acids, polyorthoesters, polyether esters, polyesters, polyamides, polyesteramides, polydepsidpetides, aliphatic polyurethanes, polysaccharides, polyhydroxyalkanoates, and copolymers thereof.


Additionally, the frames could be comprised of any number of other polymers. In another embodiment, metals and polymers may be used to fabricate said tube in a composite, laminate reinforced material, or one that is simply coated with the material. Depending on desired characteristics, tubes may be constructed of materials with specific attributes. For example, in applications where the tube will be expanded and must remain so with little or no creep or re-constriction (that is it must “lock in place”), plastically deformable materials may be chosen for monolithic constructs. Conversely, should a tube need to remain compliant, meaning remaining capable of some degree of radial re-contraction and re-expansion, elastic materials may be chosen. It will be recognized that combining materials with different functional or behavioral attributes may be effected in selected instances. The configuration of the tubes of the invention may be varied to produce selected benefits. In one embodiment, the components making up the frames (the struts) are asymmetrically wrapped along the entire length of the frame. However, in other embodiments, asymmetrically-wrapped frames can be interspersed and connected to torsionally-stable symmetrically-wrapped tube sections, the latter serving to transmit torque.


Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the figures should not be construed as limiting.

Claims
  • 1. An implantable medical device comprising: a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame; anda continuous film formed of expanded polytetrafluoroethylene (ePTFE) defining a tubular member attached to the frame, the continuous film having a microstructure of nodes and fibrils, the continuous film being oriented with the frame such that the fibrils extend along and are axially aligned with the plurality of struts, the fibrils configured to shear relative to one another within the continuous film to facilitate maintaining alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame, wherein the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.
  • 2. The implantable medical device of claim 1, wherein the fibrils extend in parallel with the plurality of struts.
  • 3. The implantable medical device of claim 1, wherein the geometry of the plurality of struts changes in response to at least one of the length change of the frame and the circumferential change of the frame, and the fibrils are configured to orient with the plurality of struts in a direction extending toward the proximal end of the frame and a direction extending toward the distal end of the frame.
  • 4. The implantable medical device of claim 1, wherein the plurality of struts include a first set of struts that extend at a first pitch toward the proximal end and a second set of struts that extend at a second pitch toward the distal end, and the fibrils include a first set of fibrils that extend at approximately the first pitch toward the proximal end and a second set of fibrils that extend at approximately the second pitch toward the distal end.
  • 5. The implantable medical device of claim 4, wherein the first set of fibrils overlap with the second set of fibrils throughout the tubular member.
  • 6. The implantable medical device of claim 1, wherein the tubular member is configured to allow expansion and contraction of the frame in response to at least one of the length change of the frame, the circumferential change of the frame, and an angular displacement of the frame.
  • 7. The implantable medical device of claim 6, wherein the tubular member is configured to resist residual elastic strain acting against frame deformation in response to at least one of the length change of the frame, the circumferential change of the frame, and the angular displacement of the frame.
  • 8. A method comprising: deploying an implantable medical device into a body, the implantable medical device including a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame and a continuous film formed of expanded polytetrafluoroethylene (ePTFE) and defining a tubular member attached to the frame, the continuous film having a microstructure of nodes and fibrils, the continuous film being oriented with the frame such that the fibrils extend along and are axially aligned with the plurality of struts in alignment with the plurality of struts; andmaintaining alignment of the fibrils by shearing relative to one another to maintain alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame with the plurality of struts in response to altering a geometry of the stent, wherein the plurality of struts are braided and extend helically between the proximal end and the distal end of the frame, and the fibrils are configured to coincide with a geometry of the plurality of struts.
  • 9. The method of claim 8, wherein maintaining alignment of the fibrils includes the fibrils shearing relative to one another to maintain alignment with the plurality of struts in response to at least one of the length change of the frame and the circumferential change of the frame.
  • 10. An implantable medical device comprising: a frame having a plurality of struts overlapping and extending between a proximal end and a distal end of the frame; anda continuous film formed of expanded polytetrafluoroethylene (ePTFE) defining a tubular member attached to the frame, the continuous film having a microstructure of nodes and fibrils, the continuous film being oriented with the frame such that the fibrils extend along and are axially aligned with the plurality of struts, the fibrils configured to shear relative to one another within the continuous film to facilitate maintaining alignment with the plurality of struts in response to at least one of a length change of the frame and a circumferential change of the frame, wherein the plurality of struts include a first set of struts that extend at a first pitch toward the proximal end and a second set of struts that extend at a second pitch toward the distal end, and the fibrils include a first set of fibrils that extend at approximately the first pitch toward the proximal end and a second set of fibrils that extend at approximately the second pitch toward the distal end.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application national phase application of PCT Application No. PCT/US2018/054915, internationally filed on Oct. 9, 2018, which claims the benefit of U.S. Provisional Application No. 62/569,805, filed Oct. 9, 2017, the entire contents of which are incorporated herein by reference for all purposes.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2018/054915 10/9/2018 WO
Publishing Document Publishing Date Country Kind
WO2019/074869 4/18/2019 WO A
US Referenced Citations (206)
Number Name Date Kind
3953566 Gore Apr 1976 A
4187390 Gore Feb 1980 A
4332035 Mano Jun 1982 A
4877661 House et al. Oct 1989 A
4955899 Della et al. Sep 1990 A
5026513 House et al. Jun 1991 A
5064435 Porter Nov 1991 A
5071609 Tu et al. Dec 1991 A
5476589 Bacino Dec 1995 A
5534007 St et al. Jul 1996 A
5549663 Cottone, Jr. Aug 1996 A
5673102 Suzuki et al. Sep 1997 A
5708044 Branca Jan 1998 A
5718973 Lewis et al. Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5749852 Schwab et al. May 1998 A
5752934 Campbell et al. May 1998 A
5759192 Saunders Jun 1998 A
5769884 Solovay Jun 1998 A
5772884 Tanaka et al. Jun 1998 A
5788626 Thompson Aug 1998 A
5814405 Branca et al. Sep 1998 A
5824043 Cottone, Jr. Oct 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5843171 Campbell et al. Dec 1998 A
5853419 Imran Dec 1998 A
5925061 Ogi et al. Jul 1999 A
5935162 Dang Aug 1999 A
5957974 Thompson et al. Sep 1999 A
6010529 Herweck et al. Jan 2000 A
6013854 Moriuchi Jan 2000 A
6042588 Munsinger et al. Mar 2000 A
6042605 Martin et al. Mar 2000 A
6042606 Frantzen Mar 2000 A
6110198 Fogarty et al. Aug 2000 A
6156064 Chouinard Dec 2000 A
6161399 Jayaraman Dec 2000 A
6165211 Thompson Dec 2000 A
6174329 Callol et al. Jan 2001 B1
6190406 Duerig et al. Feb 2001 B1
6217609 Haverkost Apr 2001 B1
6245012 Kleshinski Jun 2001 B1
6261320 Tam et al. Jul 2001 B1
6261620 Leadbeater Jul 2001 B1
6315791 Gingras et al. Nov 2001 B1
6336937 Vonesh et al. Jan 2002 B1
6352552 Levinson et al. Mar 2002 B1
6379382 Yang Apr 2002 B1
6423091 Hojeibane Jul 2002 B1
6436132 Patel et al. Aug 2002 B1
6461665 Scholander Oct 2002 B1
6488701 Nolting et al. Dec 2002 B1
6541589 Baillie Apr 2003 B1
6620190 Colone Sep 2003 B1
6626939 Burnside et al. Sep 2003 B1
6673102 Vonesh et al. Jan 2004 B1
6673107 Brandt et al. Jan 2004 B1
6716239 Sowinski Apr 2004 B2
6730120 Berg et al. May 2004 B2
6755856 Fierens et al. Jun 2004 B2
6758858 Mccrea et al. Jul 2004 B2
6890350 Walak May 2005 B1
7022132 Kocur Apr 2006 B2
7049380 Chang et al. May 2006 B1
7083642 Sirhan et al. Aug 2006 B2
7105018 Yip et al. Sep 2006 B1
7306729 Bacino et al. Dec 2007 B2
7419678 Falotico Sep 2008 B2
7462675 Chang et al. Dec 2008 B2
7531611 Sabol et al. May 2009 B2
7704274 Boyle et al. Apr 2010 B2
7789908 Sowinski et al. Sep 2010 B2
7811314 Fierens et al. Oct 2010 B2
7815763 Fierens et al. Oct 2010 B2
7887562 Young et al. Feb 2011 B2
7927364 Fierens et al. Apr 2011 B2
7927365 Fierens et al. Apr 2011 B2
7935141 Randall et al. May 2011 B2
7967829 Gunderson et al. Jun 2011 B2
8048440 Chang et al. Nov 2011 B2
8545525 Surti et al. Oct 2013 B2
8585753 Scanlon et al. Nov 2013 B2
8728103 Surti et al. May 2014 B2
8801774 Silverman Aug 2014 B2
8936634 Irwin et al. Jan 2015 B2
9241695 Peavey et al. Jan 2016 B2
9345601 Jantzen et al. May 2016 B2
9399085 Cleek et al. Jul 2016 B2
9554786 Carley et al. Jan 2017 B2
9681948 Levi et al. Jun 2017 B2
9737422 Armstrong et al. Aug 2017 B2
9795496 Armstrong et al. Oct 2017 B2
9833343 Burnside et al. Dec 2017 B2
9839540 Armstrong et al. Dec 2017 B2
9931193 Cully et al. Apr 2018 B2
10166128 Armstrong et al. Jan 2019 B2
10279084 Goepfrich et al. May 2019 B2
10335298 Armstrong et al. Jul 2019 B2
10507124 Armstrong et al. Dec 2019 B2
20010032009 Layne Oct 2001 A1
20010053929 Vonesh et al. Dec 2001 A1
20020038140 Yang et al. Mar 2002 A1
20020076542 Kramer et al. Jun 2002 A1
20020161388 Samuels et al. Oct 2002 A1
20020198588 Armstrong et al. Dec 2002 A1
20030055494 Bezuidenhout et al. Mar 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030180488 Lim et al. Sep 2003 A1
20040024442 Sowinski et al. Feb 2004 A1
20040024448 Chang et al. Feb 2004 A1
20040044400 Cheng et al. Mar 2004 A1
20040044401 Bales et al. Mar 2004 A1
20040093065 Yachia et al. May 2004 A1
20040098095 Burnside May 2004 A1
20040133266 Clerc et al. Jul 2004 A1
20040162606 Thompson Aug 2004 A1
20040170782 Wang et al. Sep 2004 A1
20040224442 Grigg Nov 2004 A1
20040260277 Maguire Dec 2004 A1
20050080476 Gunderson et al. Apr 2005 A1
20050137680 Ortiz et al. Jun 2005 A1
20050273149 Tran et al. Dec 2005 A1
20050283224 King Dec 2005 A1
20060009835 Osborne et al. Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060036311 Nakayama et al. Feb 2006 A1
20060106337 Blankenship May 2006 A1
20060118236 House et al. Jun 2006 A1
20060135985 Cox et al. Jun 2006 A1
20060161241 Barbut et al. Jul 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060259133 Sowinski et al. Nov 2006 A1
20060271091 Campbell et al. Nov 2006 A1
20060276883 Greenberg et al. Dec 2006 A1
20070012624 Bacino et al. Jan 2007 A1
20070060999 Randall et al. Mar 2007 A1
20070088421 Loewen Apr 2007 A1
20070129786 Beach et al. Jun 2007 A1
20070207186 Scanlon et al. Sep 2007 A1
20070207816 Spain, Jr. Sep 2007 A1
20070208421 Quigley Sep 2007 A1
20070213800 Fierens et al. Sep 2007 A1
20070250146 Cully et al. Oct 2007 A1
20070250153 Cully et al. Oct 2007 A1
20070254012 Ludwig et al. Nov 2007 A1
20080051876 Ta et al. Feb 2008 A1
20080097301 Alpini et al. Apr 2008 A1
20080097401 Trapp et al. Apr 2008 A1
20080097579 Shanley et al. Apr 2008 A1
20080097582 Shanley et al. Apr 2008 A1
20080119943 Armstrong et al. May 2008 A1
20080319531 Doran et al. Dec 2008 A1
20090005854 Huang et al. Jan 2009 A1
20090030499 Bebb et al. Jan 2009 A1
20090036976 Beach et al. Feb 2009 A1
20090043373 Arnault et al. Feb 2009 A1
20090104247 Pacetti Apr 2009 A1
20090182413 Burkart et al. Jul 2009 A1
20090306762 Mccullagh et al. Dec 2009 A1
20090306766 Mcdermott et al. Dec 2009 A1
20100016940 Shokoohi et al. Jan 2010 A1
20100094394 Beach et al. Apr 2010 A1
20100094405 Cottone Apr 2010 A1
20100106240 Duggal et al. Apr 2010 A1
20100159171 Clough Jun 2010 A1
20100211166 Miller et al. Aug 2010 A1
20100241214 Holzer et al. Sep 2010 A1
20100256738 Berglund Oct 2010 A1
20100286760 Beach et al. Nov 2010 A1
20100305682 Furst Dec 2010 A1
20110009953 Luk et al. Jan 2011 A1
20110087318 Daugherty et al. Apr 2011 A1
20120323211 Ogle et al. Dec 2012 A1
20130131780 Armstrong et al. May 2013 A1
20130183515 White Jul 2013 A1
20130184807 Kovach et al. Jul 2013 A1
20130197624 Armstrong et al. Aug 2013 A1
20130204347 Armstrong et al. Aug 2013 A1
20130245745 Vong et al. Sep 2013 A1
20130253466 Campbell et al. Sep 2013 A1
20130297003 Pinchuk Nov 2013 A1
20140121746 Kusleika et al. May 2014 A1
20140135897 Cully et al. May 2014 A1
20140172066 Goepfrich et al. Jun 2014 A1
20140180402 Bruchman et al. Jun 2014 A1
20150005870 Kovach et al. Jan 2015 A1
20150157770 Cully et al. Jun 2015 A1
20150313871 Li et al. Nov 2015 A1
20160015422 De et al. Jan 2016 A1
20160184079 Scutti et al. Jun 2016 A1
20170065400 Armstrong et al. Mar 2017 A1
20170105854 Treacy et al. Apr 2017 A1
20170106176 Taft et al. Apr 2017 A1
20170216062 Armstrong et al. Aug 2017 A1
20180177583 Cully et al. Jun 2018 A1
20190125517 Cully et al. May 2019 A1
20190209739 Goepfrich et al. Jul 2019 A1
20190216592 Cully et al. Jul 2019 A1
20200022828 Armstrong et al. Jan 2020 A1
20200179663 Mcdaniel et al. Jun 2020 A1
20210038413 Cully et al. Feb 2021 A1
20210068996 Armstrong et al. Mar 2021 A1
20210077246 Cully et al. Mar 2021 A1
20210138121 Cully et al. May 2021 A1
20210236139 Connor Aug 2021 A1
Foreign Referenced Citations (76)
Number Date Country
2462509 Apr 2003 CA
101420913 Apr 2009 CN
101926699 Dec 2010 CN
201744060 Feb 2011 CN
102015009 Apr 2011 CN
103945796 Jul 2014 CN
105025848 Nov 2015 CN
0293090 Nov 1988 EP
0313263 Apr 1989 EP
0582870 Feb 1994 EP
0775472 May 1997 EP
0815806 Jan 1998 EP
0893108 Jan 1999 EP
1666003 Jun 2006 EP
1946721 Jul 2008 EP
2255750 Dec 2010 EP
02-000645 Jan 1990 JP
09-241412 Sep 1997 JP
11-197252 Jul 1999 JP
11-290448 Oct 1999 JP
11-512635 Nov 1999 JP
2001-509702 Jul 2001 JP
2007-526098 Sep 2007 JP
2008-506459 Mar 2008 JP
2008-173461 Jul 2008 JP
2010-500107 Jan 2010 JP
2010-504174 Feb 2010 JP
2010-535075 Nov 2010 JP
2015-513931 May 2015 JP
2018-134425 Aug 2018 JP
2019-048083 Mar 2019 JP
2021-122433 Aug 2021 JP
2124986 Jan 1999 RU
9413224 Jun 1994 WO
9416802 Aug 1994 WO
9505555 Feb 1995 WO
9509586 Apr 1995 WO
9607370 Mar 1996 WO
9640348 Dec 1996 WO
9710871 Mar 1997 WO
9926558 Jun 1999 WO
0041649 Jul 2000 WO
0047271 Aug 2000 WO
0164278 Sep 2001 WO
0174272 Oct 2001 WO
0260506 Aug 2002 WO
0303946 Jan 2003 WO
0320175 Mar 2003 WO
2004000375 Dec 2003 WO
2006019626 Feb 2006 WO
2006058322 Jun 2006 WO
2008021002 Feb 2008 WO
2008028964 Mar 2008 WO
2008036870 Mar 2008 WO
2008049045 Apr 2008 WO
2008021006 Aug 2008 WO
2008097589 Aug 2008 WO
2009017827 Feb 2009 WO
2009100210 Aug 2009 WO
2009108355 Sep 2009 WO
2010006783 Jan 2010 WO
2010008570 Jan 2010 WO
2010030766 Mar 2010 WO
2010132707 Nov 2010 WO
2010150208 Dec 2010 WO
2011098565 Aug 2011 WO
2011132634 Oct 2011 WO
2012011261 Jan 2012 WO
2012099979 Jul 2012 WO
2012158944 Nov 2012 WO
2013074663 May 2013 WO
2013074990 May 2013 WO
2013109337 Jul 2013 WO
2013138789 Sep 2013 WO
2017038145 Mar 2017 WO
2019074869 Apr 2019 WO
Non-Patent Literature Citations (4)
Entry
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2018/054915, mailed on Apr. 2, 2019, 18 pages.
Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2.
Nishi S, Nakayama Y, Ishibashi-Ueda H, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356.
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2018/054915, mailed on Apr. 23, 2020, 14 pages.
Related Publications (1)
Number Date Country
20200237497 A1 Jul 2020 US
Provisional Applications (1)
Number Date Country
62569805 Oct 2017 US